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ABSTRACT
Objective
To evaluate whether an epidural steroid injection or
gabapentin is a better treatment for lumbosacral
radiculopathy.
Design
A multicenter randomized study conducted between
2011 and 2014. Computer generated randomization
was stratified by site. Patients and evaluating
physicians were blinded to treatment outcomes.
Settings
Eight military, Veterans Administration, and civilian
hospitals.
Participants
145 people with lumbosacral radicular pain secondary
to herniated disc or spinal stenosis for less than four
years in duration and in whom leg pain is as severe or
more severe than back pain.
Interventions
Participants received either epidural steroid injection
plus placebo pills or sham injection plus gabapentin.
Main outcome measures
Average leg pain one and three months after the
injection on a 0-10 numerical rating scale. A positive
outcome was defined as a ≥2 point decrease in leg
pain coupled with a positive global perceived effect.
All patients had one month follow-up visits; patients
whose condition improved remained blinded for their
three month visit.
Results
There were no significant differences for the primary
outcome measure at one month (mean pain score 3.3
(SD 2.6) and mean change from baseline −2.2 (SD 2.4) in
epidural steroid injection group versus 3.7 (SD 2.6) and
−1.7 (SD 2.6) in gabapentin group; adjusted difference
0.4, 95% confidence interval −0.3 to 1.2; P=0.25) and
three months (mean pain score 3.4 (SD 2.7) and mean

What is already known about this topic
Gabapentin and epidural steroid injections are often used to treat lumbosacral
radiculopathy and can provide benefit for a subset of patients, but we do not know
which treatment works better

What this study adds
Both epidural steroid injections and gabapentin treatment resulted in significant
improvements in pain scores and functional capacity
Although epidural steroid injections might be superior to gabapentin in some
outcome measures, the differences are small and generally short lived
the bmj | BMJ 2015;350:h1748 | doi: 10.1136/bmj.h1748

change from baseline −2.0 (SD 2.6) versus 3.7 (SD 2.8)
and −1.6 (SD 2.7), respectively; adjusted difference 0.3,
−0.5 to 1.2; P=0.43). Among secondary outcomes, one
month after treatment those who received epidural
steroid injection had greater reductions in worst leg pain
(−3.0, SD 2.8) than those treated with gabapentin (−2.0,
SD 2.9; P=0.04) and were more likely to experience a
positive successful outcome (66% v 46%; number
needed to treat=5.0, 95% confidence interval 2.8 to 27.0;
P=0.02). At three months, there were no significant
differences between treatments.
Conclusions
Although epidural steroid injection might provide
greater benefit than gabapentin for some outcome
measures, the differences are modest and are
transient for most people.
Trial registration
ClinicalTrials.gov Identifier: NCT01495923.

Introduction
The physical, socioeconomic, and psychological impact
of low back pain is enormous. Low back pain has been
the leading cause of years lost to disability over the past
several decades,1 with a lifetime prevalence that ranges
between 50% and 90%.2 3 The economic cost is
estimated to exceed $100 bn a year in the United States
(£67 bn, €93 bn), over half of which can be attributed to
lost productivity.3 4 Efforts to deal with the worldwide
burden posed by low back pain have become an international priority.
The classification of back pain is perhaps the most
important distinction for clinicians to make as it influences investigation and treatment decisions at all levels
of care.5 Since the development of validated instruments to categorize low back pain,6 7 studies have determined that the proportion of chronic cases that are
predominantly neuropathic (that is, sciatica, radicular
pain from a herniated disc, or neurogenic claudication
from spinal stenosis) ranges between 17% and 55%,7-11  
with one review finding a median prevalence rate of
41%.12 Whereas the presence of neuropathic symptoms
portends a more negative prognosis for acute episodes,13 lumbosacral radicular pain might be more
responsive to procedural interventions than non-
specific back pain.12 14
Epidural steroid injections are the most commonly
performed procedure for pain relief in the world,15
being more commonly used and more effective for
radicular pain than mechanical spine pain. 12 16
Although mixed, most controlled studies have also
1
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found pharmacotherapy with gabapentinoids can be
effective for lumbosacral radicular pain.17-21
Numerous controlled trials have been performed to
evaluate epidural steroid injections and drug treatment
in people with low back pain, with review articles generally reporting modest effects.12 22 Yet for clinicians, the
more relevant question is not whether a real treatment
is better than a sham treatment, but which treatment is
more effective.23
Several small randomized open label studies have
looked at epidural steroid injections compared with
drug treatment. One study showed superiority for a single epidural steroid injection at one month but not later
follow-up compared with tramadol and a muscle relaxant.24 A second study showed that a single caudal epidural steroid injection provided better pain relief than
non-steroidal anti-inflammatory drugs through three
months.25 Neither study evaluated first line adjuvant
treatments (such as gabapentin) as a comparison
group. A more recent three armed multicenter study
was performed in 169 patients with cervical radiculopathy. Over six months participants received nortriptyline and/or gabapentin plus physical therapies, up to
three cervical epidural steroid injections, or combination treatment in which they received both injections
and conservative care. They found that the combination
group experienced a higher success rate at three
months but not six months.26 Although these studies
might simulate real life decisions facing clinicians, the
fact that none were blinded precludes any conclusions
regarding efficacy. We investigated a single epidural steroid injection compared with gabapentin in patients
with lumbosacral radicular pain in a double blinded
fashion.

Methods
Participants and settings
The study sites were four joint service military treatment facilities, three of which serve as teaching hospitals (Walter Reed, San Diego, and San Antonio) and one
of which is located in Europe; a Veteran’s Administration hospital; and three civilian teaching hospitals
(Johns Hopkins, Case Western, and Penn State).
All participants were treated between 15 December
2011 and 10 June 2014. Inclusion criteria were age ≥17;
an average score for radicular leg pain of ≥4 on a 0-10
numerical rating scale over the preceding week or 3/10
if the leg pain was as bad as or worse than back pain;
current symptoms had lasted for more than six weeks
and up to four years; and signs (such as straight leg
raising test) and/or symptoms (such as lower leg pain)
of lumbosacral radicular pain. All participants were
also required to have findings of a herniated disc or spinal stenosis on magnetic resonance imaging, concordant with their presentation. Patients were permitted
to have symptoms in more than one dermatome.
Exclusion criteria were neuropathic pain for more
than four years in duration; previous failed trial with, or
adverse reaction to, gabapentin or pregabalin; epidural
steroid injections within the past three years; cauda
equina syndrome; referrals for surgical evaluation;
2

 revious lumbar spine surgery; pregnancy; allergic
p
reaction to contrast dye; known secondary gain (such
as active litigation); active infection; and serious medical (such as poorly controlled diabetes, cirrhosis, recent
myocardial infarction, congestive heart failure, or
unstable angina) or psychiatric condition (such as
dementia, poorly controlled post-traumatic stress syndrome as indicated by a score ≥44 on the post-traumatic
stress disorder checklist,27 substance abuse, somatization disorder, or depression as indicated by a Beck
Depression score ≥2128) that might preclude an optimal
response to treatment. Because our intention was to
evaluate the relative effects of two commonly used
treatments for radicular pain, we also excluded patients
with neurogenic claudication from spinal stenosis who
did not report lower leg pain (that is, those who had
only weakness or paresthesias). Although heterogeneity is often desirable in comparative effectiveness trials,
we performed briefings, debriefings, full time access to
a senior investigator, and at one site practice enrollments to enhance selection consistency.

Randomization and interventions
We randomized 145 participants in a 1:1 ratio by computer generated randomization tables. An investigator
physician enrolled participants, stratified by study site.
Research nurses performed allocation in groups of 36 at
Walter Reed and Johns Hopkins as these sites were
expected to enroll more patients, and in groups of 18 at
other sites, with treatment allocated with a sequentially
numbered opaque sealed envelope before injection.
Larger allocation blocks were used to promote allocation concealment with investigators. Participants at
each site were suballocated separately on a 1:1 ratio
based on the type of epidural steroid injection they
received: those with unilateral pain received unilateral
transforaminal epidural steroid injections, while those
with bilateral pain underwent interlaminar epidural
steroid injections. The patient, research nurse, and
evaluating physician were blinded to assignment.
Epidural injections
A board certified pain medicine physician conducted or
supervised all procedures using fluoroscopic guidance.
The segmental level at which the injection was administered was selected based on signs, symptoms, and
radiological findings. For interlaminar injections, a
Tuohy needle was inserted in or near the midline and
advanced into the epidural space with image guidance
in the anteroposterior and lateral views by using the
loss of resistance technique. For transforaminal epidural steroid injections, a 22 gauge spinal needle was
inserted coaxially into the upper part of the targeted
foramina with the imagine intensifier positioned in an
oblique plane. Correct placement was confirmed with
the injection of contrast, which showed bilateral spread
for all interlaminar injections and proximal epidural
uptake for all transforaminal procedures. Once the
physician was satisfied with the pattern of contrast spread,
a solution consisting of 60 mg of depomethylprednisolone +1 mL of 0.25% bupivacaine was administered.
doi: 10.1136/bmj.h1748 | BMJ 2015;350:h1748 | the bmj
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For those who received interlaminar injections, the
injectate was diluted in normal saline to a volume of
4 mL; in the transforaminal subgroup, the total volume
administered was 3 mL. Whereas some physicians routinely perform multilevel transforaminal injections, we
limited our procedures to a single level to minimize
risks because there are no controlled studies validating
the use of more than one injection and because a well
placed transforaminal epidural steroid injection generally spreads to multiple levels.29 30

an affirmative response to the following two statements:32 “My pain has improved/ worsened/stayed the
same since my last visit” and “I am satisfied/not satisfied with the treatment I received and would/would not
recommend it to others.”
Because patients cannot accurately distinguish
between neuropathic pain (which is more likely to
respond to epidural steroid injection and gabapentin)12 33
and mechanical pain, we separately recorded leg (neuropathic) and back (mechanical) pain scores as surrogates. Whereas a small percentage of cases of axial back
Sham injections and maintenance of blinding
pain might be neuropathic in nature,34 and many forms
Participants were instructed ahead of time that they of mechanical pain such as facet arthropathy and
might or might not experience paresthesias during the degenerative disc disease can radiate into the leg,35 valprocedure and were visually shielded from the image idated instruments have shown that leg pain emanating
screen. The same technique (such as trajectory and use from the back is generally indicative of radicular pain.7
The Oswestry disability index is a 10 question survey
of multiplanar fluoroscopy) was used for injections
except in sham injections the needle was positioned 1-2 cm used to assess function in people with low back and/or
proximal to the epidural space into the posterior liga- leg pain in which higher scores indicate greater levels of
ments. A small volume of saline was then injected in disability. The classification of spinal stenosis was made
lieu of contrast, followed by an additional 3 mL to sim- if the participant had moderate or severe canal stenosis
ulate the injectate. A generic note was entered into the (<12 mm) not attributable to a herniated disc. We assessed
medical record without radiographs.
complications by asking fixed and open ended questions
one day after injections and at all follow-up visits. In addiPharmacotherapy
tion to individual variables, we predesignated a positive
A central research pharmacy over-capsulated 300 mg composite outcome (that is, successful procedure) to be a
gabapentin and placebo capsules to appear identical. decrease of ≥2 points in average leg pain score coupled
Before each shipment, the capsules were tested to with a positive global perceived effect.36
In those individuals who experienced a positive outensure potency, or lack thereof for group 2. Titration
schedules were prepared on a case-to-case basis in come at one month, the final follow-up occurred at
accordance with standard practice, but dosing targets three months. In these individuals, in addition to rescue
generally ranged from 1800 mg/day to 3600 mg/day medications, the study drug could also be titrated
three times a day. Drugs were generally up-titrated over upwards. For ethical reasons, those with a negative outa period of 15 to 24 days, with the only caveat being that come at one month left the study “per protocol” to
a therapeutic dose range had to be obtained at least five receive non-study interventions, which is consistent
with other randomized interventional studies.26 32 37 38
days before follow-up.
We imputed missing data points for pain scores,
Co-interventions, outcome measures, follow-up,
Oswestry disability index, and the composite outcome
using the “last observation carried forward” method,
and missing data
No contact with the investigative team was permitted which can underestimate effect sizes when “dropouts”
during the study. Tramadol and non-steroidal anti- occur because of lack of efficacy.39
inflammatory drugs could be prescribed on an “as
needed” basis as rescue medications (or opioids could Statistical analysis
be increased by up to 20% for those taking opioids), but We used an intention to treat strategy for all analyses.
no other co-interventions were permitted. Participants We calculated differences in treatment effects and 95%
were provided with instructions on how to taper their confidence intervals for pain and disability scores with
analgesic drugs based on response. An investigator analysis of covariance (ANCOVA) adjusting for baseline
blinded to treatment carried out the first follow-up visit values of outcome measures. An indicator of the treatone month after the start of treatment. The primary out- ment group was coded such that positive values favored
come measure was the average leg pain score on a 0-10 the epidural steroid injection group. No correction was
numerical rating scale recorded at one and three prespecified for multiple comparisons. Because of a difmonths, reflecting the average pain experienced during ference in sex distribution at baseline, we adjusted post
the week before follow-up. Predefined secondary out- hoc analysis of outcomes for sex. We used logistic
come measures included worst leg pain over the past regression models to compare the proportion of patients
week, average and worst back pain, score on the with adverse events in the first month and factors assoOswestry disability index (version 2.0, MODEMS, Des ciated with binary outcomes in post hoc analysis. We
Plaine, IL),31 adverse effects and complications, reduc- used Poisson regression models with robust standard
tion in analgesic drugs (>20% reduction in opioid use or errors to analyze adverse event rates. Effectiveness of
complete cessation of non-opioid analgesics), and blinding in each treatment group was evaluated by
global perceived effect, which was defined as not using two indices. In the James blinding index40 (range
requiring further non-rescue interventions along with 0-1), 0 indicates total absence of blinding, 1 indicates
the bmj | BMJ 2015;350:h1748 | doi: 10.1136/bmj.h1748
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Table 1 | Baseline demographic and clinical characteristics of participants in study of
epidural steroid injections compared with gabapentin for lumbosacral radicular pain.
Figures are numbers of participants (percentage) unless stated otherwise
Characteristic

Epidural steroid
injection (n=73)

Gabapentin
(n=72)

Mean (SD age (years)

43.8 (14.0)

41.7 (11.9)

Women*

25 (34)

13 (18)

Duration of pain:
<3 months:

11 (15)

15 (21)

3-<months

26 (36)

27 (38)

1-3 years

27 (37)

23 (32)

>3 years

9 (12)

7 (10)

Treatment with opioids:
None

54 (74)

55 (7)

<60 morphine equivalents/day

16 (22)

14 (19)

≥60 morphine equivalents/day

3 (4)

Mean (SD) oral morphine equivalents among opioid users (mg/day) 28.7 (34.8)

3 (4)
38.5 (53.0)

Diagnosis:
Herniated nucleus pulposus

63 (85)

65 (90)

Spinal stenosis

10 (14)

7 (10)

Active duty military:
Any

38 (52)

41 (57)

Enlisted

26 (36)

30 (42)

Officer

12 (16)

11 (15)

Inciting event:
None

42 (58)

41 (60)

Motor vehicle crash

1 (1)

1 (1)

Fall

5 (7)

9 (13)

Lifting

13 (18)

6 (8)

Sports/training

8 (11)

13 (18)

Other†

4 (6)

2 (3)

Pain related to deployment

10 (14)

6 (8)

Current smoker‡

15 (21)

13 (18)

Obesity

13 (18)

19 (26)

Psychiatric comorbidity:
None

56 (77)

49 (68)

Mood

9 (12)

12 (17)

Anxiety

7 (10)

6 (8)

Substance abuse

3 (4)

4 (6)

Post-traumatic stress disorder

1 (1)

4 (6)

Other§

1 (1)

3 (4)

Multiple diagnoses

4 (6)

6 (8)

Injection approach:
Interlaminar

11 (15)

12 (17)

Transforaminal

62 (85)

60 (83)

Level of injection:
L2-3

1 (1)

0

L3-4

1 (1)

2 (3)

L4-5

22 (30)

18 (25)

L5-S1

44 (60)

46 (64)

S1

5 (7)

6 (8)

Mean (SD) baseline pain scores¶:
Average leg pain

5.4 (2.1)

5.4 (1.9)

Worst leg pain

7.9 (1.7)

7.8 (2.0)

Average back pain

5.0 (2.6)

4.7 (2.4)

Worst back pain

7.0 (2.6)

7.0 (2.9)

Oswestry disability score

39.8 (15.3)

39.8 (14.7)

*Significant difference between two groups (P=0.027 by χ2 test).
†Includes post-surgical, pregnancy, spinal tap, and work related.
‡Includes three participants who chew tobacco products.
§Includes attention deficit hyperactivity disorder and obsessive compulsive disorder.
¶Based on 0-10 numerical rating scale scores.
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complete blinding, and 0.5 indicates completely random
blinding. In the Bang blinding index41 (range −1-1), −1
indicates that all patients guessed the incorrect treatment, 0 indicates all patients randomly guessed, and 1
indicates all patients guessed the correct treatment. We
conducted subgroup analyses to ascertain which demographic and clinical variables were associated with outcome. Variables examined included etiology (such as
stenosis v herniated disc), level of injection, pain duration ≥3 months, injection type (for instance, transfo
raminal epidural steroid injection for unilateral pain
v interlaminar epidural steroid injection for bilateral
pain), smoking status, military status, presence of psychiatric disease, obesity, age, sex, and gabapentin dose.
We had intended to examine the effect of inciting events
related to war, such as traumatic brain injury, but there
were too few patients to render any analysis meaningful.
We used Bonferroni-corrected significance thresholds
for post hoc subgroup analyses, with corrected P values
calculated as 0.05 divided by the number of comparisons being made. All other reported P values were based
on two sided tests, with <0.05 considered significant.
The study was powered to evaluate the effectiveness
of epidural steroid injections compared with gabapentin. Assumptions include a difference of 1 point in pain
scores between groups at one month, standard deviation of each group of 2 based on data from previous
studies, a retention rate of 87%, and a two sided α level
of 0.05. Although a 30% or 2 point decrease in pain has
been shown to represent a clinically meaningful benefit
to an individual patient, the same IMMPACT (Initiative
on Methods, Measurement and Pain Assessment in
Clinical Trials) guidelines note that smaller differences
between groups can be considered to be clinically
important in clinical trials.36 We chose a 1 point difference in pain scores because it is consistent with US
Food and Drug Administration requirements for
approval of adjuvant analgesic drugs for low back pain
and gabapentin for neuropathic pain.42 43

Patient involvement
Although non-scientists from the surrounding communities served on many of the approving review boards at
participating institutions, patients did not participate
in the design of this study. All participants will receive
the results of the study and a copy of the final manuscript from their study team by email or post.
Results
We assessed 348 potential participants, of whom 147
were eligible for inclusion and agreed to participate. Of
these, 145 were assigned to receive either an epidural
steroid injections and sham drug (n=73) or gabapentin
and a sham injection (n=72). The two groups were similar with respect to baseline characteristics, except that
the epidural steroid injection group contained more
women (table 1 , figure).
Outcomes
At one month, both the epidural steroid injection group
and the gabapentin group experienced improvement in
doi: 10.1136/bmj.h1748 | BMJ 2015;350:h1748 | the bmj
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Patients assessed for eligibility (n=348)
Excluded (n=203):
Failed to meet inclusion and/or exclusion criteria (such as previous surgery, no MRI
correlation, long duration of pain, coexisting medical or psychiatric conditions) (n=127)
Eligible but declined to participate (n=74)
Withdrew before randomization (n=2)
Randomized (n=145)

Allocated to receive epidural steroid
injection and placebo gabapentin (n=73)

Allocated to receive gabapentin
and sham injection (n=72)

Did not receive treatment (n=0)
Received treatment (n=73):
Interlaminar approach (n=11)
Transforaminal approach (n=62)
1 month
follow-up
and
primary
analysis

Did not receive treatment (n=0)
Received treatment (n=72):
Interlaminar approach (n=12)
Transforaminal approach (n=60)

Lost to follow-up (n=2)

Lost to follow-up (n=0)

Completed assessment and
included in analysis (n=71)

3 month
follow-up
and
analysis

Completed assessment and
included in analysis (n=72)

Had negative outcome
and exited study (n=23)

Had negative outcome
and exited study† (n=39)

Withdrew from study (n=7)
Lost to follow-up (n=0)

Withdrew from study (n=0)
Lost to follow-up (n=1)

Completed 3 month assessment* and
were included in analysis (n=41)

Completed 3 month assessment and
were included in analysis (n=32)

* Includes eight participants with early 3 month evaluations because of return of pain to baseline level
† Includes one participant who sought emergency care and one with unstable angina who was started on opioids,
both unrelated to treatment

Flow of progress of participants through clinical trial of epidural steroid injections and
gabapentin in people with lumbosacral radicular pain

the average leg pain score (mean 3.3 points (SD 2.6) and
mean change from baseline −2.2 points (SD 2.4) in epidural steroid injection group versus 3.7 points (SD 2.6)
and −1.7 points (SD 2.6) in gabapentin group), but no
significant difference between groups was observed
(adjusted difference 0.4 points, 95% confidence interval
−0.3 to 1.2; P=0.25) (table 2). At three months, improvements in average leg pain score persisted (mean 3.4
points (SD 2.7) and −2.0 points (SD 2.6) versus mean 3.7
points (SD 2.8) and −1.6 points (SD 2.7), respectively),
but again with no significant difference between groups
(0.3 points, −0.5 to 1.2; P=0.43).
For secondary outcome measures, there were small
differences between groups favoring epidural steroid
injections at one month for worst leg pain score
(adjusted difference 0.9 points, 95% confidence interval
0.0 to 1.9; P=0.04 (table 2 )) and successful outcome
(66% and 46%, P=0.02 (table 3 ); number needed to
treat 5.0, 95% confidence interval 2.8 to 27.0). For average back pain at one month, there was a moderate
improvement for the epidural steroid injections group
(−1.5, SD 1.9) and a mild improvement for the gabapentin group (−1.1, SD 2.3), but the differences were not significant (adjusted difference 0.3 points, −0.4 to 0.9;
P=0.45) (table 2). No significant differences were
observed for outcomes at three months or for patients
proceeding to surgery within one year of enrollment (9
(13%) in epidural steroid injection group v 10 (15%) in
gabapentin group; P=0.73) (table 3).

Factors associated with outcome and post hoc
analyses
In subgroup analyses, military officers were more likely
to experience a positive outcome than either enlisted

Table 2 | Outcomes related to pain and disability in people with lumbosacral radicular pain according to treatment with epidural steroid injections or
gabapentin*
Epidural steroid injection

Average leg pain:
Baseline
1 month
3 months
Worst leg pain:
Baseline
1 month
3 months
Average back pain:
Baseline
1 month
3 months
Worst back pain:
Baseline
1 month
3 months
Oswestry disability score‡:
Baseline
1 month
3 months

Gabapentin

Treatment comparison

No of
patients

Overall
mean (SD)

Mean change
from baseline

No of
patients

Overall
mean (SD)

Mean change
from baseline

Adjusted difference
(95% CI)†

P value

73
73
73

5.4 (2.1)
3.3 (2.6)
3.4 (2.7)

—
−2.2 (2.4)
−2.0 (2.6)

72
72
72

5.4 (1.9)
3.7 (2.6)
3.7 (2.8)

—
−1.7 (2.6)
−1.6 (2.7)

—
0.4 (−0.3 to 1.2)
0.3 (−0.5 to 1.2)

—
0.25
0.43

73
73
73

7.9 (1.7)
4.9 (3.1)
5.2 (3.4)

—
−3.0 (2.8)
−2.7 (3.2)

72
72
72

7.8 (2.0)
5.8 (3.0)
5.5 (3.4)

—
−2.0 (2.9)
−2.3 (3.5)

—
0.9 (0.0 to 1.9)
0.3 (−0.7 to 1.4)

—
0.04
0.54

73
73
73

5.0 (2.6)
3.5 (2.6)
3.9 (2.7)

—
−1.5 (1.9)
−1.1 (2.4)

72
72
72

4.7 (2.4)
3.6 (2.6)
3.7 (2.5)

—
−1.1 (2.3)
−1.0 (2.4)

—
0.3 (−0.4 to 0.9)
−0.1 (−0.8 to 0.6)

—
0.45
0.85

73
73
72

7.0 (2.6)
5.1 (2.9)
5.6 (3.2)

—
−1.9 (2.4)
−1.4 (2.9)

72
72
72

7.0 (2.9)
5.4 (3.2)
5.6 (3.1)

—
−1.6 (2.6)
−1.4 (2.8)

—
0.3 (−0.4 to 1.1)
0.0 (−0.8 to 0.9)

—
0.38
0.91

73
73
73

39.8 (15.3)
32.6 (18.3)
33.6 (19.4)

—
−7.3 (12.5)
−6.2 (15.8)

72
72
72

39.8 (14.7)
29.6 (16.0)
29.6 (16.3)

—
−10.2 (14.5)
−10.2 (16.7)

—
−2.9 (−7.2 to 1.3)
−3.9 (−9.0 to 1.1)

—
0.18
0.12

*Data for missing 1 month and 3 months outcomes including pain scores, Oswestry disability scores imputed by last observed outcome carried forward. Numerical rating scores for pain are
based on 0-10 numerical rating scales, with 0 indicating no pain and 10 indicating severe pain.
†Differences for pain and Oswestry disability scores adjusted for baseline values. Negative coefficients favor gabapentin group. Positive coefficients favor epidural steroid injection group.
‡10 question survey used to assess function in people with low back and/ or leg pain, in which higher scores indicate greater levels of disability.26
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Table 3 | Further outcomes in people with lumbosacral radicular pain according to
treatment with epidural steroid injections or gabapentin
Epidural steroid
injection

Gabapentin

No of
patients

No of
patients

No (%)

P value for
comparison

No (%)

Reduction in drug treatment*:
4 weeks

67

40 (60)

65

32 (49)

0.23

12 weeks

40

23 (58)

30

14 (47)

0.37

1 month

73

49 (67)

72

41 (57)

0.21

3 months

73

33 (45)

72

24 (33)

0.14

1 month

73

48 (66)

72

33 (46)

0.02

3 months

73

27 (37)

72

21 (29)

0.32

72

9 (13)

69

10 (14)

0.73

Global perceived effect (positive)†:

Composite outcome (positive)†‡:

Proceeded to surgery within year
of enrollment

*Reduction in analgesics corresponds to >20% reduction in opioid use or complete cessation of non-opioid
analgesics. Patients who were not on pain drugs were excluded from this analysis.
†Missing data for 1 month and 3 months imputed by last observed outcome carried forward.
‡>2 point decrease in average leg pain coupled with positive global perceived effect without additional
procedural or non-rescue pharmacological interventions.

personnel or non-service members at one month (odds
ratio 6.7, 95% confidence interval 1.8 to 24.6; P=0.004).
Injection at S1 was associated with a greater reduction
in leg pain than at other levels (−0.7, −0.1 to −1.2; P=0.02)
but failed to reach significance when we adjusted for
multiple comparisons. We found no associations
among the primary or composite outcomes at one
month based on etiology (such as stenosis v herniated
disc), pain duration ≥3 months, injection type (transforaminal epidural steroid injections for unilateral pain v
interlaminar epidural steroid injections for bilateral
pain), smoking status, presence of psychiatric disease,
obesity, age, sex, or dose of gabapentin. In post hoc
adjustments for sex, the difference between groups in
reduction of worst leg pain favoring epidural steroid
injections was no longer significant (0.3, −0.8 to 1.4;
P=0.05).

Adverse events
The proportion of patients reporting one or more
adverse events from the injection was 8% (n=6) in the
epidural steroid injection group and 10% (n=7) in the
gabapentin group (P=0.75). The proportion of patients
reporting one or more adverse events from drug treatment was 42% (n=30) in the epidural steroid injection
group and 51% (n=37) in the gabapentin group (P=0.24;
table 4).
Blinding
We assessed blinding at two time points: immediately
after the procedure to assess blinding for real epidural
steroid injections and at the first follow-up to ensure
blinding for real gabapentin. Immediately after the
baseline procedure, patients were unaware of assigned
treatments (James blinding index 0.75, 95% confidence
interval 0.69 to 0.80; P=1.0; Bing blinding index 0.07
(−0.07 to 0.21) in the epidural steroid injections group
and −0.24 (−0.38 to −0.09) in gabapentin group),
6

i ndicating successful blinding. At one month, the overall success of blinding was maintained (James blinding
index 0.56, 0.49 to 0.63; P=0.93), though there was a
trend towards better insight into treatment assignment
for the gabapentin group (Bing blinding index 0.08
(−0.07 to 0.25) in epidural steroid injection group and
0.19 (0.03 to 0.36) in gabapentin group).

Discussion
Principal findings and study rationale
In people with lumbosacral radicular pain randomized
to epidural steroid injections or gabapentin, we found
that although there were some small differences in favor
of the injections at one month, there were no significant
differences for our primary outcome measure (average
leg pain one and three months), and the differences
observed mostly disappeared at three months. Although
only a small percentage of our patients had spinal stenosis, our findings are consistent with a recent multicenter study that found modest short term benefit for
epidural steroid injections for this condition.44 In our
study we compared epidural steroid injections with epidural local anesthetic, which a systematic review
showed was superior to soft tissue control injections
(that is, not a placebo).45 We elected to use a “true placebo” (intramuscular injection), which is more difficult
to blind but unlikely to provide benefit, and included
patients with both spinal stenosis and herniated disc.
Broad inclusion criteria enhance generalization and are
consistent with guidelines on comparative effectiveness
research.46 47
The rationale for this comparative efficacy study is
that there are well over 50 published clinical trials epidural steroid injections or adjuvants compared with
placebo for radiculopathy, but none that compared one
treatment with another. In accordance with the US
Department of Health and Human Services recommendation to increase and improve comparative effectiveness research,46 we decided to compare two of the most
common treatments for lumbosacral radicular pain in a
double blind fashion.46
Comparison with other studies
Results of placebo controlled studies evaluating gabapentinoids and other membrane stabilizers for radiculopathy are mixed, indicating a probable small effect
size.48 This suggests that differences between groups
are unlikely to represent a large treatment effect.
Although myriad reviews on epidural steroid injections
have yielded disparate conclusions, recent systematic
and evidence based reviews have indicated that any
stand alone treatment effect for epidural steroid injections is likely to be modest and short lived.12 22
In a recent open label three arm comparative effectiveness study pitting a series of epidural steroid injections against conservative therapy consisting of
pharmacotherapy (gabapentin and/or nortriptyline)
and physical therapy, and the combination of the two,
it was found that combination treatment with epidural
steroid injections plus drugs and physical therapy provided superior benefit to stand alone treatment on some
doi: 10.1136/bmj.h1748 | BMJ 2015;350:h1748 | the bmj
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Table 4 | Adverse events in people with lumbosacral radicular pain according to
treatment with epidural steroid injections or gabapentin. *Figures are numbers
(percentage) of participants unless stated otherwise
Adverse event

Related to injection
Injection received
≥1 event*
Total adverse events (event rate)†
Reported symptoms or events:
Excessive pain
Fever, infection, or both
Falls
Vasovagal
Other§
Related to drug treatment
Treatment received
Mean (SD) dose (mg)
Compliance¶:
None
Partial (50-89%)
Full (>90%)
≥1 event*¶
Total adverse events (event rate)*¶
Reported symptoms or events¶:
Sedation/fatigue
Cognitive
Weight gain
Headache
Gastrointestinal
Swelling
Other**

Epidural steroid injection
group (n=73)

Gabapentin group
(n=72)

P value

Epidural steroid injections
6 (8)
6 (0.08)

Sham injection
7 (10)
9 (0.13)

—
0.75
0.42

2‡
2
1‡
0
1

4‡
0
0
2‡
3

—
—
—
—
—

Sham pills
2132.9 (609.4)

Gabapentin pills
2095.8 (678.3)

—
0.73

6 (8)
11 (15)
55 (76)
30 (42)
45 (0.63)

8 (11)
8 (11)
56 (78)
37 (51)
50 (0.69)

0.68

8 (11)
5 (7)
4 (6)
4 (6)
13 (18)
0 (0)
11 (15)

13 (18)‡
7 (10)‡
7 (10)‡
1 (1)
8 (11)‡
3 (4)‡
11 (15)‡

—
—
—
—
—
—
—

0.24
0.61

*Significance assessed with logistic regression model adjusted for treatment group assignment.
†Significance assessed with Poisson regression model with robust standard errors adjusted for treatment group
assignment.
‡Deemed related to or possibly related to treatment.
§Other adverse events for epidural steroid injection group include “low cortisol noted on lab tests three weeks
after injection in patient also receiving oral steroids with no symptoms.” Other adverse events for gabapentin
group (sham injection) include bruising, temporary inability to lift legs, and “GI bleed after three days in patient
receiving low molecular weight heparin.” None deemed related to treatment.
¶Data missing for one patient in epidural steroid injection group.
**Other adverse events for epidural steroid injection group (placebo pills) include ataxia, balance problems,
depression, emotionality, kidney stones, muscle twitching, hot flashes, restlessness, rhinorrhea with
congestion, sexual, vivid dreams, and one without description. Other adverse events for gabapentin group
include blackout, ‡ depression requiring admission to hospital, dizziness (2), ‡dry mouth (2), ‡leg spasms, mood
changes, rhinorrhea with flu-like symptoms, and one without description.

outcome measures.26 In some respects, the open label
format and inclusion of a multimodal treatment
approach might better reflect “real life” circumstances,
though they preclude the evaluation of efficacy.

Explanation of findings
There are several possible explanations for our findings. The first is that both treatments are equally effective, but the effects dissipate over time. Unlike studies
of epidural steroid injections that often follow patients
for up to one year,49-54 few studies have examined the
long term effectiveness of gabapentin, but those that
have indicate that the beneficial effects for neuropathic
pain are most pronounced early on during treatment.55
56 A second hypothesis is that neither treatment is effective, and the benefits observed were caused by a placebo response or the natural course of the disease.
Those with chronic radiculopathy, however, are less
the bmj | BMJ 2015;350:h1748 | doi: 10.1136/bmj.h1748

likely than those with shorter duration of symptoms to
spontaneously improve or respond to treatment.57
A third possibility is that epidural steroid injections are
superior to gabapentin, but the relatively small sample
size, the use of only one injection, treatment blinding,
and our failure to reinforce the short term benefit with
physical therapy rendered three month differences
indistinguishable. In their effectiveness study that compared a series of epidural steroid injections, neuropathic adjuvants plus physical therapy, and
combination therapy for cervical radiculopathy, Cohen
and colleagues reported that the better outcomes in the
combination group might have been attributable to the
ability of physical therapy to reinforce the short term
gains afforded by procedures.26

Strengths and limitations
The main strength of our study is that we compared
two of the most commonly used treatments for lumbosacral radiculopathy pain in a double blind fashion at
institutions that reflect the gamut of settings in which
patients might seek treatment. There are several limitations to our study, including the primary outcome
being measured at one month, which was necessary
because we allowed those with an unsuccessful outcome to seek other treatments, and the lack of a true
placebo group, which renders the assay sensitivity
questionable. Without a true placebo group, one cannot assess the true efficacy of the two treatments.
A third limitation is that we did not permit repeat epidural steroid injections or allow combination drug
treatment. Studies have shown there is little basis for
a rote “series” of epidural steroid injections, though
some might benefit from repeat injections, which are
often performed in clinical practice.12 26 32 44 54 58 59 Similarly, randomized studies have shown that combination treatment with drugs that include gabapentinoids
could provide superior relief for neuropathic and low
back pain compared with treatment with a single
agent.60 A fourth limitation inherent in our design is
that blinding of participants might have altered our
findings. “Blinding” is not a tenet of comparative
effectiveness research, which seeks to determine the
best treatment in “real world” conditions. The placebo
effect is especially powerful for subjective measures
such as pain and stronger for procedures than for pills,
which might have mitigated any “real world” differences between treatments.61 62 A final limitation is our
broad inclusion criteria, which included patients taking opioids and those with herniated disc and spinal
stenosis. These conditions are characterized by
slightly different pathophysiological mechanisms and
might have different natural outcomes. A larger study
would be needed to determine whether certain
patients (such as those with herniated disc versus spinal stenosis) or treatments (transforaminal versus
interlaminar epidural steroid injections) experience
better outcomes than others. In practice, patients generally receive epidural steroid injections and/or adjuvants regardless of the etiology of their neuropathic
pain. In clinical trials, most epidural s teroid injection
7
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studies12 24–26 32 49 51 53 and all gabapentinoid studies17-21
included both etiologies, with most studies finding no
difference in outcomes with epidural steroid injection12 or gabapentinoid (R Baron, personal communication, 2014)20 21 between people with stenosis and
disc herniation.

Generalizability
These results are readily generalizable to primary care
settings, pain clinics, and spine surgery centers, where
practitioners are often faced with the question about
the best non-operative way to manage lumbosacral
radicular pain. Future studies might include both placebo and combination groups (for example, factorial
design), allow for multiple injections and drugs, and
require physical therapy in an effort to determine
whether any observed benefit could be prolonged. The
logistical and ethical obstacles in designing such studies (such as blinding multiple drugs or performing
multiple sham injections in patients who fail to
respond to the first one), however, will make them difficult to execute.
Conclusions and policy implications
Gabapentin and epidural steroid injections used to treat
lumbosacral radicular pain both resulted in modest
improvements in pain and function, which persisted
through three months. Although some differences
favored epidural steroid injections, these tended to be
small and transient. The similar outcomes between
treatment groups on most measures suggest that a trial
with neuropathic drugs might be a reasonable first line
treatment option.
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